NCT02954900

Brief Summary

The purpose of this pilot study is to evaluate a decision support website (RealRisks) designed to inform patients about breast cancer chemoprevention. It is coupled with a physician-centered (BNAV) decision support website as part of clinical workflow in the primary care setting. The investigator hypothesizes that improving accuracy of breast cancer risk perception and understanding of the risks/benefits of chemoprevention will enhance informed decision-making and uptake of breast cancer prevention strategies in the primary care setting.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 15, 2016

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

July 12, 2016

Completed
4 months until next milestone

First Posted

Study publicly available on registry

November 4, 2016

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2018

Completed
Last Updated

January 8, 2021

Status Verified

January 1, 2021

Enrollment Period

2.5 years

First QC Date

July 12, 2016

Last Update Submit

January 7, 2021

Conditions

Keywords

Breast Cancer PreventionRisk AssessmentChemopreventionDecision Making

Outcome Measures

Primary Outcomes (1)

  • Change in the accuracy of risk perception (Likert Scale Score)

    To measure the patient's accuracy of perceived breast cancer risk before and after exposure to the RealRisks decision aid. Perception will be assessed by comparing the difference between a patient's perceived risk and their actual risk based on the Gail breast cancer model. Patients are asked to make a comparative risk assessment about themselves on a 3-point Likert scale.

    Baseline, 2 weeks

Secondary Outcomes (3)

  • Change in a patient's breast cancer knowledge (Survey Score)

    Baseline, 2 weeks

  • Chemoprevention uptake rate among high-risk women

    6 months

  • Referral rates to the breast clinic

    12 months

Study Arms (1)

Decision aid

OTHER

50 women at high-risk for developing breast cancer will use a decision support tool, RealRisks, when discussing breast cancer risk with their providers who will have access to the BNAV provider clinical decision support tool.

Other: RealRisksOther: BNAV

Interventions

RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.

Also known as: RealRisks patient-centered decision aid (DA)
Decision aid
BNAVOTHER

Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.

Also known as: Breast Cancer Risk Navigation (BNAV) tool, BNAV provider clinical decision support tool
Decision aid

Eligibility Criteria

Age35 Years - 75 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • year breast risk of 1.67% or lifetime risk of 20% according to the Gail model
  • The participant understands and is willing to provide informed consent in English or Spanish
  • Has a primary care provider at Columbia University Medical Center (CUMC) / New York-Presbyterian Hospital

You may not qualify if:

  • Prior use of a selective estrogen receptor modulator (SERM) or aromatase inhibitor (AI) for chemoprevention
  • Prior history of breast cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Columbia University Medical Center

New York, New York, 10032, United States

Location

Related Publications (3)

  • Kukafka R, Yi H, Xiao T, Thomas P, Aguirre A, Smalletz C, David R, Crew K. Why Breast Cancer Risk by the Numbers Is Not Enough: Evaluation of a Decision Aid in Multi-Ethnic, Low-Numerate Women. J Med Internet Res. 2015 Jul 14;17(7):e165. doi: 10.2196/jmir.4028.

    PMID: 26175193BACKGROUND
  • Yi H, Xiao T, Thomas PS, Aguirre AN, Smalletz C, Dimond J, Finkelstein J, Infante K, Trivedi M, David R, Vargas J, Crew KD, Kukafka R. Barriers and Facilitators to Patient-Provider Communication When Discussing Breast Cancer Risk to Aid in the Development of Decision Support Tools. AMIA Annu Symp Proc. 2015 Nov 5;2015:1352-60. eCollection 2015.

    PMID: 26958276BACKGROUND
  • Kukafka R, Fang J, Vanegas A, Silverman T, Crew KD. Pilot study of decision support tools on breast cancer chemoprevention for high-risk women and healthcare providers in the primary care setting. BMC Med Inform Decis Mak. 2018 Dec 17;18(1):134. doi: 10.1186/s12911-018-0716-5.

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Equipment and Supplies

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Katherine D Crew, M.D., M.S.

    Columbia University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Medicine and Epidemiology

Study Record Dates

First Submitted

July 12, 2016

First Posted

November 4, 2016

Study Start

March 15, 2016

Primary Completion

October 1, 2018

Study Completion

October 1, 2018

Last Updated

January 8, 2021

Record last verified: 2021-01

Locations